Home › Compare › DGNG vs JNJ

DGNG vs JNJ: Dividend Comparison 2026

DGNG yields 28571.43% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DGNG wins by $1.8174438113797412e+21M in total portfolio value
10 years
DGNG
DGNG
● Live price
28571.43%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8174438113797412e+21M
Annual income
$1,805,016,220,998,010,500,000,000,000.00
Full DGNG calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — DGNG vs JNJ

📍 DGNG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDGNGJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DGNG + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
DGNG pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DGNG
Annual income on $10K today (after 15% tax)
$2,428,571.43/yr
After 10yr DRIP, annual income (after tax)
$1,534,263,787,848,309,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, DGNG beats the other by $1,534,263,787,848,309,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DGNG + JNJ for your $10,000?

DGNG: 50%JNJ: 50%
100% JNJ50/50100% DGNG
Portfolio after 10yr
$908721905689870598144.00M
Annual income
$902,508,110,499,005,300,000,000,000.00/yr
Blended yield
99.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DGNG
No analyst data
Altman Z
-0.4
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DGNG buys
0
JNJ buys
0
No recent congressional trades found for DGNG or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDGNGJNJ
Forward yield28571.43% ✓2.13%
Annual dividend / share$2.00$5.20 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28% ✓
Portfolio after 10y$1.8174438113797412e+21M$30.3K ✓
Annual income after 10y$1,805,016,220,998,010,500,000,000,000.00 ✓$4,689.40
Total dividends collected$1.816625906206534e+21M$15.4K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DGNG vs JNJ ($10,000, DRIP)

YearDGNG PortfolioDGNG Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$2,867,843$2,857,142.86$10,592$272.30+$2.86M → DGNG
2$768,847,726$765,779,134.08$11,289$357.73+$768.84M → DGNG
3$192,691,632,776$191,868,965,708.97$12,123$472.89+$192691.62M → DGNG
4$45,147,257,398,343$44,941,077,351,272.53$13,141$629.86+$45147257.39M → DGNG
5$9,889,057,995,779,864$9,840,750,430,363,638.00$14,408$846.81+$9889057995.77M → DGNG
6$2,025,084,628,942,200,600$2,014,503,336,886,716,000.00$16,021$1,151.60+$2025084628942.18M → DGNG
7$387,709,524,857,534,600,000$385,542,684,304,566,450,000.00$18,122$1,588.22+$387709524857534.63M → DGNG
8$69,399,422,486,233,860,000,000$68,984,573,294,636,305,000,000.00$20,930$2,228.20+$69399422486233856.00M → DGNG
9$11,614,570,450,215,628,000,000,000$11,540,313,068,155,356,000,000,000.00$24,792$3,191.91+$11614570450215628800.00M → DGNG
10$1,817,443,811,379,741,200,000,000,000$1,805,016,220,998,010,500,000,000,000.00$30,274$4,689.40+$1.8174438113797412e+21M → DGNG

DGNG vs JNJ: Complete Analysis 2026

DGNG — Stock

Diguang International Development Co., Ltd. engages in the design, production, and distribution of small to medium-sized light emitting diode and cold cathode fluorescent lamp backlights primarily for large and medium sized companies. The company offers backlights for liquid crystal displays in various applications, such as color displays for cell phones, car televisions and navigation systems, digital cameras, televisions, computer displays, camcorders, PDAs, DVDs, CD and MP3/MP4 players, and appliance displays, as well as for indoor and outdoor lighting, and home and office use. It sells its products to customers primarily in Taiwan, Hong Kong, North America, Europe, Japan, Southeast Asia, and China Mainland. The company was founded in 2004 and is headquartered in Shenzhen, the People's Republic of China. Diguang International Development Co., Ltd. is a subsidiary of Sino Olympics Industrial Limited.

Full DGNG Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this DGNG vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DGNG vs SCHDDGNG vs JEPIDGNG vs ODGNG vs KODGNG vs MAINDGNG vs ABBVDGNG vs MRKDGNG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.